Publications by authors named "Kasper Recourt"

Claim this Profile
K
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression.
Kasper Recourt, Joop Van Gerven, Nadieh Drenth, Jeroen van der Grond, Kantaro Nishigori

Front Neurosci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.
Marije E Otto, Kirsten R Bergmann, Marieke L de Kam, Kasper Recourt, Gabriël E Jacobs

CPT Pharmacometrics Syst Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Peter van der Ark, Heike Benes, Joop M A van Gerven

Transl Psychiatry· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FHH Quick App Review: How Can a Quality Review Process Assist Primary Care Providers in Choosing a Family Health History App for Patient Care?
Grant M Wood, Sander van Boom, Kasper Recourt, Elisa J F Houwink

Genes (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.
Oleksandr Sverdlov, Jelena Curcic, Kristin Hannesdottir, Liangke Gou, Valeria De Luca, Kasper Recourt

Front Psychiatry· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Kasper Recourt, Jasper van der Aart, Gabriel Jacobs, Marieke de Kam, Wayne Drevets

J Psychopharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis